Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T20:28:21.549Z.
Calculation as of: 2026-10-06T20:28:21.549Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4b02f9201491092a18cecf2b81be2f5b28d52d90b5dbf9557ce71fef5bc65ed5
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Tvardi Therapeutics, Inc.
Market Cap
$10.13M
EV/EBITDA Ratio
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO |
|---|---|---|
| Tvardi Therapeutics, Inc. (TVRD) | $10.13M | N/A |
| Medicus Pharma Ltd. Common Stock (MDCX)vs › | $10.06M | N/A |
| Lifeward Ltd. (LFWD)vs › | $10.21M | N/A |
| Valion Bio, Inc. (VBIO)vs › | $9.86M | N/A |
| Polyrizon Ltd. (PLRZ)vs › | $10.83M | N/A |
| NeuroOne Medical Technologies Corporation (NMTC)vs › | $9.83M | N/A |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $10.45M | N/A |
| MetaVia Inc. (MTVA)vs › | $9.75M | N/A |
| Senti Biosciences, Inc. (SNTI)vs › | $10.06M | N/A |
| Satellos Bioscience Inc. (MSLE)vs › | $9.71M | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
